Last updated: February 21, 2026
Who are the primary producers of nabilone?
Nabilone, a synthetic cannabinoid used primarily for nausea and vomiting associated with chemotherapy, is manufactured predominantly by controlled substances licensees. Its synthesis, distribution, and licensing are tightly regulated globally.
Major manufacturers and licensing status
1. Canopy Growth Corporation / Bedrocan
- Location: Canada
- Product: Bedrocan produces pharmaceutical-grade nabilone under licensing agreements.
- Regulation: Operates under Canadian federal licenses for controlled substances.
- Notes: Bedrocan’s parent, Canopy Growth, supplies medicinal cannabis products but has licensed production of synthetic cannabinoids such as nabilone for specific markets.
2. AbbVie
- Location: United States
- Product: Historically marketed nabilone under the brand name Cesamet.
- Regulation: U.S. Drug Enforcement Administration (DEA) classification Schedule II.
- Notes: AbbVie held the US rights but has divested or licensed production to other entities over time.
3. Madaus (part of STADA Group)
- Location: Germany
- Product: Licenses and produces nabilone for European markets.
- Regulation: Controlled substances license for manufacturing Schedule II in Germany and EU.
4. Other Licensees
- Several generic drug manufacturers in Europe and Asia hold licenses for nabilone synthesis. These include labs in Israel, India, and China, often producing under strict licensing agreements or for local markets.
Regulatory environment and licensing
- United States: Nabilone is classified as Schedule II under the Controlled Substances Act, requiring DEA registration for manufacturing.
- Europe: Nabilone is permitted under medicinal schedules in several countries, with manufacturing licenses issued by national authorities.
- Canada: Approved for medical use, with licensed producers supplying pharmacists and hospitals.
Manufacturing specifications and supply chain considerations
- Production complexity: Synthesis of nabilone involves controlled, multi-step chemical processes adhering to Good Manufacturing Practice (GMP).
- Supply chain: Limited to licensed manufacturers due to regulatory controls; disruptions can occur due to legal changes or manufacturing issues.
Key points
| Aspect |
Details |
| Main producers |
Bedrocan (Canada), AbbVie (US), Madaus (Germany) |
| Regulatory status |
Schedule II (US), controlled substance in EU/Canada |
| Licensing requirements |
Stringent, involving DEA and national authorities |
| Market availability |
Restricted to licensed manufacturers, pharmacies, hospitals |
Key Takeaways
- Nabilone is produced mainly by licensed manufacturers within strict regulatory frameworks.
- Major suppliers include Bedrocan, AbbVie, and Madaus.
- Production is limited by legal restrictions, complex synthesis, and licensing agreements.
- Supply disruptions could arise from regulatory changes, manufacturing issues, or licensing renegotiations.
- Global availability depends on national licensing and prescription requirements.
FAQs
Q1: Are generic versions of nabilone available?
A: Yes, in some countries, multiple licensed manufacturers produce generic nabilone, subject to local regulatory approvals.
Q2: Can consumers directly purchase nabilone from suppliers?
A: No. Nabilone is a controlled substance available only through licensed healthcare providers and pharmacies.
Q3: Which countries regulate nabilone as a Schedule II drug?
A: The United States, Canada, and European countries such as Germany regulate nabilone as a Schedule II or equivalent controlled substance.
Q4: What's the typical licensing process for manufacturing nabilone?
A: Manufacturers must obtain controlled substances licenses from relevant authorities, demonstrate GMP compliance, and adhere to strict security and record-keeping measures.
Q5: Are there supply chain challenges for nabilone?
A: Yes. Production complexity, regulatory requirements, and licensing restrictions limit supply, increasing dependence on a few licensed producers.
References
- U.S. Drug Enforcement Administration. (2021). Controlled Substances Scheduling. https://www.dea.gov
- Health Canada. (2022). Controlled Drugs and Substances Licenses. https://www.canada.ca
- European Medicines Agency. (2020). German Federal Institute for Drugs and Medical Devices. https://www.bfarm.de
- Bedrocan. (2022). Product Portfolio. https://bedrocan.com/
- AbbVie. (2018). Product information on Cesamet. https://abbvie.com
